Re: Nivolumab plus Cabozantinib Versus Sunitinib for Advanced Renal-cell Carcinoma
- PMID: 33992475
- DOI: 10.1016/j.eururo.2021.04.039
Re: Nivolumab plus Cabozantinib Versus Sunitinib for Advanced Renal-cell Carcinoma
Comment on
-
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.N Engl J Med. 2021 Mar 4;384(9):829-841. doi: 10.1056/NEJMoa2026982. N Engl J Med. 2021. PMID: 33657295 Free PMC article. Clinical Trial.
Similar articles
-
Comparison of the Efficacy and Safety of Nivolumab Plus Cabozantinib versus Sunitinib in the Treatment of Elderly Patients with Advanced Clear Cell Renal Cell Carcinoma.Arch Esp Urol. 2024 Jun;77(5):584-590. doi: 10.56434/j.arch.esp.urol.20247705.79. Arch Esp Urol. 2024. PMID: 38982788
-
Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma.Clin Drug Investig. 2022 Jul;42(7):611-622. doi: 10.1007/s40261-022-01170-6. Epub 2022 Jun 13. Clin Drug Investig. 2022. PMID: 35696045 Free PMC article.
-
Cost-Effectiveness Analysis of First-Line Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma in the United States.Adv Ther. 2021 Dec;38(12):5662-5670. doi: 10.1007/s12325-021-01926-0. Epub 2021 Oct 18. Adv Ther. 2021. PMID: 34664194
-
Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma.Target Oncol. 2022 Mar;17(2):193-201. doi: 10.1007/s11523-022-00866-1. Epub 2022 Feb 17. Target Oncol. 2022. PMID: 35175500 Review.
-
Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review.Cancer Treat Rev. 2022 Feb;103:102333. doi: 10.1016/j.ctrv.2021.102333. Epub 2021 Dec 24. Cancer Treat Rev. 2022. PMID: 35033866 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical